| study reports presence of loss-of-function mutations and deletions of the EZH2 and SUZ12 genes, which encode components of the Polycomb repressive complex 2 (PRC2), in 25% of T cell acute lymphoblastic leukemias; study suggesst tumor suppressor role for PRC2 in leukemia and suggest a gnized dynamic interplay between oncogenic NOTCH1 and PRC2 | leukemia, |
| studies suggest a tumor suppressor role for PRC2 in human leukemia and suggest a hitherto unrecognized dynamic interplay between oncogenic NOTCH1 and PRC2 function | leukemia, |
| PRC2 is a tumor suppressor in Emicro-myc lymphomagenesis, because disease onset was accelerated by heterozygosity for Suz12 or by short hairpin RNA-mediated knockdown of Suz12 or Ezh2. | lymphoma, |
| We show that, in contrast to PRC1, PRC2 is a tumor suppressor in Emicro-myc lymphomagenesis in lymphoma. | lymphoma, |
| the polycomb group gene SUZ12 functions as tumour suppressor in peripheral nerve sheath tumors, high-grade gliomas and melanomas by cooperating with mutations in NF1 | skin,glioma, |
| Mutations of SUZ12 and EED are reported to have tumor suppressive functions. (Review) | None |
| SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. | lung, |
| provide evidences suggesting that SUZ12 is an oncogene in non-small cell lung cancer | lung, |
| SUZ12 protein is significantly up-regulated and associates with cervical node metastasis in primary head and neck squamous cell carcinoma.SUZ12 might serve as a putative oncogene by promoting cell proliferation, migration and invasion in head and neck squamous cell carcinoma. | cervical,HNSC, |
| SUZ12 is indispensable for USP3-mediated oncogenic activity in gastric cancer. | gastric, |
| Nucleosome binding enabled by Jarid2 and Aebp2 is in part accounted for by the structures, which also reveal that disruption of the Jarid2-Suz12 interaction may underlie the disease mechanism of an oncogenic chromosomal translocation of Suz12. | None |